How Antidepressant Use Affects Life Insurance Decisions
Insurers view antidepressant medication as a signal of mental health risk, which can increase perceived mortality and affect underwriting. They assess the type of drug, dosage, treatment duration, and any related diagnoses to estimate the likelihood of future claims.
More from this site
Keep reading the latest coverage
Key Factors Insurers Evaluate
Underwriters look at several specific elements when you disclose antidepressant use:
- Medication class (e.g., SSRIs, SNRIs, tricyclics)
- Dosage level and stability of the regimen
- Length of treatment and any recent changes
- Underlying diagnosis and its severity
- Presence of co‑occurring conditions such as hypertension or substance use
Common Reasons for Decline
Typical reasons a policy is denied include:
- Recent initiation of therapy (usually within the past 6‑12 months)
- High‑dose or multiple psychiatric medications
- Documented suicide attempts or self‑harm
- Uncontrolled depressive episodes that affect daily functioning
Improving Your Chances of Acceptance
Take these steps to strengthen your application:
- Maintain stable medication for at least 12 months before applying.
- Provide comprehensive medical records showing symptom control.
- Seek a second opinion or a letter from your psychiatrist confirming low risk.
- Consider a guaranteed‑issue or simplified issue policy if traditional underwriting remains challenging.
Alternative Coverage Options
If a standard policy remains out of reach, explore these alternatives:
- Term life policies with simplified issue (no medical exam).
- Guaranteed‑issue whole life policies, though premiums are higher.
- Accidental death and dismemberment (AD&D) coverage, which excludes health‑related causes.
Table: Medication Class vs. Typical Underwriting Impact
| Class | Typical Impact | Notes |
|---|---|---|
| SSRIs (e.g., Prozac, Zoloft) | Standard‑plus rating | Often acceptable after 6‑12 months of stability. |
| SNRIs (e.g., Effexor, Cymbalta) | Standard‑plus or preferred‑plus | Depends on dosage and co‑morbidities. |
| Tricyclics (e.g., Amitriptyline) | Standard‑plus or sub‑standard | Higher side‑effect profile raises scrutiny. |
| MAOIs (e.g., Nardil) | Sub‑standard | Rarely prescribed; considered higher risk. |